TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03875196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training With Biofeedback
Description: Biyofeedback: The Biyofeedback allows the patient to see the results of her behavior immediately By a perineometer device or electromyelography that is placed in the vagina, the patient sees how she hears the pelvic floor muscles, hears the sound or hears her voice, and detects how much she needs to contract.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training With Biofeedback
Description: Biyofeedback: The Biyofeedback allows the patient to see the results of her behavior immediately By a perineometer device or electromyelography that is placed in the vagina, the patient sees how she hears the pelvic floor muscles, hears the sound or hears her voice, and detects how much she needs to contract.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Magnetic Innervation
Description: Extracorporeal Magnetic Innervation: The patients are seated in a special chair connected to an external power unit and a magnetic field generator inside with their clothes on. In order to coincide the spreading magnetic field with pelvic floor muscles, the urethral and anal sphincters, the perineum of the patients should be placed in the center of the chair. In this way, the perineum tissues are stimulated by emitted magnetic field waves. Thus no electrical current passes through the device to the patient's body and the patient is exposed to only the magnetic current.
Study: NCT04589884

Intervention type: OTHER
Intervention: Hyperspectral Imaging
Description: Hyperspectral images of the operative field will be collected at several time points during the surgical procedure. The device used is the TIVITA® compact Hyperspectral imaging system (Diaspective Vision GmbH, Germany). It is a CE (European Economic Area) mark approved device. The acquisition takes roughly 10 seconds, is contrast-free and contact-free.

Intervention type: OTHER
Intervention: Hyperspectral Imaging
Description: Hyperspectral images of the operative field will be collected at several time points during the surgical procedure. The device used is the TIVITA® compact Hyperspectral imaging system (Diaspective Vision GmbH, Germany). It is a CE (European Economic Area) mark approved device. The acquisition takes roughly 10 seconds, is contrast-free and contact-free.

Intervention type: OTHER
Intervention: Hyperspectral Imaging
Description: Hyperspectral images of the operative field will be collected at several time points during the surgical procedure. The device used is the TIVITA® compact Hyperspectral imaging system (Diaspective Vision GmbH, Germany). It is a CE (European Economic Area) mark approved device. The acquisition takes roughly 10 seconds, is contrast-free and contact-free.

Intervention type: OTHER
Intervention: Hyperspectral Imaging
Description: Hyperspectral images of the operative field will be collected at several time points during the surgical procedure. The device used is the TIVITA® compact Hyperspectral imaging system (Diaspective Vision GmbH, Germany). It is a CE (European Economic Area) mark approved device. The acquisition takes roughly 10 seconds, is contrast-free and contact-free.

Intervention type: OTHER
Intervention: Hyperspectral Imaging
Description: Hyperspectral images of the operative field will be collected at several time points during the surgical procedure. The device used is the TIVITA® compact Hyperspectral imaging system (Diaspective Vision GmbH, Germany). It is a CE (European Economic Area) mark approved device. The acquisition takes roughly 10 seconds, is contrast-free and contact-free.
Study: NCT00549549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: indomethacin 50 mg three times a day (TID) for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 50 mg two times a day (BID) for 8 days
Study: NCT02224781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study: NCT04226014

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound
Description: Echo-endoscopy ultrasound is an examination that presents little risk. However, any medical act, exploration, intervention even conducted under conditions of competence and safety in accordance with current data of medicine and the regulations in force, conceals a risk of complications. In particular, esophageal perforations can occur. They are often favored by underlying lesions (tumor, diverticulum, anatomical variants ...). Other complications are possible such as cardiovascular, respiratory or infectious disorders, as with any anesthesia.
Study: NCT01951118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease. For patients who do not tolerate donepezil or have a history of intolerance to donepezil or cannot take donepezil for other reasons, treatment with other cholinesterase inhibitors (galantamine or rivastigmine) is permitted at any stage of the protocol. Data will be analyzed in two ways: for donepezil alone, and for any cholinesterase inhibitor (donepezil or rivastigmine or galantamine) as the intervention.
Study: NCT01678664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg per day of everolimus during 24 months or until progression disease

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: embolization
Description: 2 sessions embolization with spheric particles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
Study: NCT03171597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Regulating Drugs
Description: Mainly including statins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Regulating Drugs
Description: Mainly including statins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Regulating Drugs
Description: Mainly including statins

Intervention type: DRUG
Group type: OTHER
Intervention: Lipid Regulating Drugs
Description: Mainly including statins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coronary Vasodilator
Description: Mainly including nitrates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coronary Vasodilator
Description: Mainly including nitrates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coronary Vasodilator
Description: Mainly including nitrates

Intervention type: DRUG
Group type: OTHER
Intervention: Coronary Vasodilator
Description: Mainly including nitrates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Decoction
Description: Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gualou Xiebai Banxia Decoction & Danshen Decoction
Description: Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuanghe Decoction
Description: Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
Study: NCT03881202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoNS Treatment
Description: PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages
Study: NCT03848793

Intervention type: DRUG
Group type: OTHER
Intervention: HS-20004
Description: treatment

Intervention type: DRUG
Group type: OTHER
Intervention: HS-20004
Description: treatment

Intervention type: DRUG
Group type: OTHER
Intervention: HS-20004
Description: treatment

Intervention type: DRUG
Group type: OTHER
Intervention: HS-20004
Description: treatment
Study: NCT02651337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebrospinal Fluid (CSF) Drainage
Description: Placement of Alivio in line flusher during CSF drainage
Study: NCT04186221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Liver System
Description: OCS Liver System for preserving and assessing donor livers for transplantation
Study: NCT02960230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: K27M peptide
Description: K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: K27M peptide
Description: K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: K27M peptide
Description: K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: anti-programmed cell death protein 1 (PD-1) monoclonal antibody
Study: NCT02468999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: human insulin
Study: NCT02158377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trabecular metal dental implants (TM)
Description: Patients receive TM dental implants in this arm. The early stability is measured and compared to the stability of the TSV implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered screw-vent implants (TSV)
Description: Patients receive TSV dental implants in this arm. The early stability is measured and compared to the stability of the TM implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
Study: NCT01134393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan/amlodipine
Description: start low dose and uptitrate to high dose on the basis of BP goal
Study: NCT02635256

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiosurgery
Description: Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife
Study: NCT00531947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline Transdermal System
Description: EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
Study: NCT01119820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Donation
Description: Females over 18 who are scheduled to undergo elective surgery will have discarded tissue collected.
Study: NCT03828227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPTIMOX-bevacizumab
Description: Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~* Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks \[q2w\]),~* Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~* Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~* 5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~* No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~* Bevacizumab: 5 mg/kg IV (day 1, q2w),~* FA: 400 mg/m² IV/2h (day 1, q2w),~* 5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~* No 5-FU bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine plus bevacizumab
Description: * Bevacizumab: 7.5 mg/kg intravenous infusion \[IV\] (day 1; q3w),~* Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine plus bevacizumab
Description: * Bevacizumab: 7.5 mg/kg intravenous infusion \[IV\] (day 1; q3w),~* Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w).
Study: NCT00700128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: frovatriptan
Description: Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: frovatriptan
Description: frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT00655642

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
Study: NCT01269970

Intervention type: OTHER
Intervention: 18-FDG-PET-CT
Study: NCT01925755

Intervention type: OTHER
Intervention: Rivaroxaban ( Xarelto, BAY59-7939)
Description: Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg
Study: NCT05116228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500mg RTX Group
Description: Patients will receive 1x500mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1000mg RTX Group
Description: Patients will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
Study: NCT00700128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT00537290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000mg IV on Days 0 and 15
Study: NCT03046953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: anti-PDL1 antibody
Study: NCT03143777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sara Combilizer
Description: Combined tilt table and stretcher chair
Study: NCT02799277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Effect of testosterone on moral decision making

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Effect of testosterone on moral decision making
Study: NCT02924233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).~Sym004 will be administered at different dose-levels via infusion Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).~Sym004 will be administered at different dose-levels via infusion Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
Study: NCT03631524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period.
Study: NCT02521441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-627
Description: F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-627
Description: F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim at dose of 5 mcg/kg/day for up to 2 weeks, s.c. start from Day 3 of each cycle for up to 4 cycles.
Study: NCT02462824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Description: The home-based exercise intervention focuses on walking exercise and consists of two phases. Phase I (weeks 1-4) consists of four on-site visits to an exercise facility, where participants will meet the telephone coach, learn to use the Fitbit activity monitor, become familiar with the study website, learn behavioral skills necessary for long-term adherence to home-based exercise, and get started on their exercise program. Phase II (weeks 5-36) is entirely home-based and includes a) use of the Fitbit for self-monitoring; and b) regularly scheduled telephone calls from the study telephone coach to monitor and support participants' home exercise activity' c) use of the study website; d) optional group telephone calls.
Study: NCT02745002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: navigated bronchoscopy
Study: NCT02743702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESPIRATORY PHYSIOTHERAPY
Description: The protocol designed was composed of the following exercises:~* supine position: inhalation and exhalation with abdominal and thoracic pressures. 5 times~* lateral decubitus, with incentive spirometer lung inflation are made on right/left sides. 3 sets on each side~* sitting position, with the body leaning slightly forward, head and shoulders bent inwardly directed. It inspire called for 3 times, sent off in air through the mouth, after that the child was coughing~* diaphragmatic breathing in a sitting position: after a slow exhalation requested, child should steam a mirror with his mouth slightly open. 3 replications~* in a sitting position, with help of an ambu bag, we made inflations. Repeated 3 times~* exercises of upper member coupled to respiratory rhythm: shoulder flexion and extension was carried out during the inspiratory phase and the extension and adduction of them during expiration. 3 times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USUAL THERAPIES

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USUAL THERAPIES